Intermittent fasting: what trials show for weight, glucose, and metabolic risk

What intermittent fasting actually refers to

Intermittent fasting is not one thing. The umbrella term covers three main patterns:

• Time-restricted eating (TRE). A daily eating window of usually 6–10 hours, with no kilojoule-containing food or drink outside the window. The most common is 16:8 (eating window of 8 hours, fast of 16 hours). “Early TRE” places the window earlier in the day (e.g. 8 am to 4 pm); “late TRE” later.
• Alternate-day fasting (ADF). Alternating ad libitum eating days with fasting or very-low-energy days. Modified ADF allows a small meal (about 500–600 kcal) on the fasting day.
• The 5:2 pattern. Two non-consecutive low-energy days per week (typically 500–600 kcal) and five days at usual intake. Popularised by Michael Mosley and the focus of the Australian-developed CSIRO Flexi Diet research.

Other variants — extended water fasts, “OMAD” (one meal a day), and prolonged fasts — exist but have less trial evidence and a higher rate of adverse effects.

The honest clinical question is not “does fasting work” but which pattern, in which person, with what supervision, and what outcome is being asked about.

A. Core clinical — what the trials actually show

Weight loss. Multiple randomised trials and meta-analyses converge on the same finding: intermittent fasting produces clinically meaningful weight loss (typically 3–8% of body weight over 8–12 weeks) when adhered to. When trials directly match intermittent fasting against standard daily calorie restriction at equivalent total energy intake, the weight-loss outcomes are similar. The 2022 NEJM trial of time-restricted eating added to calorie restriction in 139 adults with obesity in China found no additional weight loss from the 8-hour eating window over 12 months beyond calorie restriction alone — both groups lost approximately 6–8 kg.

The Trepanowski alternate-day fasting trial in 100 metabolically healthy adults with obesity found equivalent weight loss between ADF and daily calorie restriction at one year, with similar dropout rates (about 38% vs 29%).

Glucose and insulin sensitivity. Several smaller trials have shown improvements in fasting glucose, insulin sensitivity (HOMA-IR), and glucose tolerance with intermittent fasting. The Sutton early time-restricted feeding trial in eight men with prediabetes (eating window 6 hours, finishing before 3 pm) showed improvements in insulin sensitivity and beta-cell responsiveness independent of weight change — a result that has been frequently cited but is in a small, all-male, short-duration sample.

For people with established type 2 diabetes, the Carter 5:2 trial in 137 Australian adults found 5:2 equivalent to standard daily energy restriction for HbA1c reduction at 12 months. The strongest signal in this trial was adherence — both groups had similar improvements in HbA1c, and both struggled with maintenance.

Lipids. Modest reductions in LDL cholesterol and triglycerides have been reported, generally in proportion to weight loss. There is no clear evidence that intermittent fasting improves the lipid profile beyond what is achieved by the same energy reduction without time restriction.

Blood pressure. Small reductions, in proportion to weight loss.

Cardiovascular events. No randomised trial has yet been long enough or large enough to establish whether intermittent fasting reduces cardiovascular events. The 2024 American Heart Association conference abstract suggesting increased cardiovascular mortality with short eating windows was a non-peer-reviewed observational analysis of self-reported eating times — not a randomised trial — and is not currently changing clinical practice. The honest summary on hard outcomes is uncertain and awaiting longer trials.

Cancer prevention or treatment. Animal data is interesting; human trial data for cancer prevention or as cancer treatment is preliminary. Intermittent fasting is not recommended as a cancer treatment. People undergoing cancer treatment should not begin intermittent fasting without oncology input, particularly during chemotherapy or radiotherapy.

B. Evidence appraisal and controversies

The “metabolic switch” narrative. Popular accounts attribute the benefits of intermittent fasting to ketogenesis, autophagy, or a “metabolic switch” that occurs after 12–16 hours of fasting. The trial evidence is consistent with a simpler explanation: the benefits scale with energy reduction. Where time-restricted eating reduces total energy intake (as it often does — fewer hours of eating typically means fewer kilojoules), it produces benefits. Where total energy intake is matched, the benefits are similar between intermittent fasting and standard calorie restriction. Mechanism research is interesting but does not yet justify clinical claims about autophagy, longevity, or “switching” into a fundamentally different metabolic mode.

Length of fasting window. The shortest “intermittent fasting” — a 12-hour overnight fast from dinner to breakfast — overlaps with what many adults do already and has limited additional effect. Most of the trial benefit comes from windows of 8–10 hours of eating and 14–16 hours of fasting. Extending beyond a 16-hour daily fast does not appear to add benefit and adds adherence difficulty and side effects.

Early vs late eating window. A small but consistent signal supports placing the eating window earlier in the day (e.g. 8 am to 4 pm), based on circadian biology of insulin sensitivity. Most people find this socially impractical. The effect, where present, is small. Late-window TRE (e.g. 12 pm to 8 pm) is more sustainable and still shows benefit, with somewhat less metabolic effect.

Muscle mass and lean tissue. Concerns about muscle loss on intermittent fasting are reasonable in older adults and in people doing significant resistance training. Adequate protein intake (≥1.2 g/kg/day, distributed across the eating window) and resistance exercise during the intervention period substantially mitigate this risk.

Hunger, irritability, and headaches are common in the first 1–2 weeks and usually settle. Persistent symptoms suggest the pattern is not a good fit.

Adherence in real life. Drop-out rates in trials are 20–40% across patterns. Long-term maintenance of any dietary pattern — including intermittent fasting — is the central problem in weight management, not the choice of pattern.

The eating-disorder caution. Intermittent fasting structures (rules about when to eat, identity around restraint, the “fasting wins”) can be a trigger for or a continuation of restrictive eating patterns. Beyond Blue, the Butterfly Foundation, and InsideOut Institute all flag intermittent fasting as inappropriate for people with current or past eating-disorder history. The clinical history matters here — a brief screen with the SCOFF questionnaire is reasonable before recommending an IF pattern.

Hypoglycaemia in diabetes treatment. People with type 2 diabetes on metformin alone are typically safe to fast. People on insulin or sulfonylureas (gliclazide, glimepiride, glibenclamide) are at meaningful risk of hypoglycaemia on fasting days and need medication adjustment and medical supervision before starting any intermittent fasting pattern.

Drug timing. Some medications need food (e.g. metformin, NSAIDs, some antibiotics). Others are best fasting (e.g. levothyroxine, bisphosphonates). The eating window has to be planned around the medication schedule, not the other way around.

C. Australian operations — what the visit might look like

In Australian general practice, a discussion about intermittent fasting is usually one piece of a broader conversation about weight, glucose, or cardiovascular risk. It happens during:

• A long consultation (item 36) or very long consultation (item 44) for chronic-disease management, weight, prediabetes, or type 2 diabetes.
• A Heart Health Check (item 699) where weight and metabolic risk are part of the assessment.
• A GP Management Plan (item 721) with Team Care Arrangement (item 723) when there is established type 2 diabetes, obesity-related comorbidity, or another chronic condition needing coordinated care. This combination opens up to five subsidised allied-health visits per calendar year, including an accredited practising dietitian, an exercise physiologist, and a diabetes educator.

(MBS / PBS items verified 2026-05-15 via WebSearch — workspace egress to mbsonline.gov.au + pbs.gov.au still blocked; spot-check confirms current.)

The clinical pre-checks before recommending an intermittent fasting pattern are practical and brief:

• Eating disorder history — past anorexia, bulimia, binge eating disorder, orthorexia, or marked food anxiety. Intermittent fasting is contraindicated.
• Pregnancy or breastfeeding — not recommended.
• Age — not recommended in children or adolescents; caution in older adults at risk of sarcopenia or undernutrition.
• Diabetes treatment — insulin or sulfonylurea: requires medication adjustment and supervision. Metformin alone: usually safe.
• Other medications — review timing against the proposed eating window.
• Gallstones, gastroparesis, gout flares, advanced kidney or liver disease — specific cautions; case-by-case.
• Body weight — not recommended in adults with BMI under 18.5 or with recent unexplained weight loss.
• Workload, shift work, and family eating patterns — the chosen pattern has to be realistic in the person’s life.

The most common pattern recommended in general practice is a 14:10 or 16:8 time-restricted eating window, anchored around the family dinner. The 5:2 pattern is a reasonable alternative, particularly for people who prefer not to alter daily structure. Strict alternate-day fasting and longer water fasts are rarely recommended in general practice.

For people with established type 2 diabetes who are interested in intermittent fasting, the most up-to-date AU clinical pathway is GP-led, with input from a diabetes educator and dietitian via a GP Management Plan, and medication adjustment by the prescribing GP or endocrinologist before starting. Diabetes Australia has consumer-facing resources.

D. Integrative considerations and how to start sensibly

A reasonable, evidence-aligned starting point for an adult who has been screened as a suitable candidate:

Step	What it looks like
1. Confirm suitability	Eating-disorder screen, pregnancy status, medications reviewed, comorbidities considered.
2. Choose a pattern that fits the life	14:10 or 16:8 time-restricted eating anchored around dinner is the most sustainable for most adults.
3. Set a 4–6 week trial period	Don’t reorganise life permanently around an unproven-for-this-person pattern.
4. Eat well inside the window	Mediterranean-pattern food, protein ≥1.2 g/kg/day distributed across meals, vegetables and legumes at most meals. Intermittent fasting is not a permit for poor food quality during eating windows.
5. Stay hydrated outside the window	Water, plain tea or coffee, no calorific drinks.
6. Track what matters	Weight if relevant, energy, sleep, mood, work performance, hunger pattern, any symptoms. HbA1c at 3 months if diabetes is the indication.
7. Review at 4–6 weeks	If the pattern is working and feeling sustainable, continue. If not, return to standard energy-balanced eating.
8. Watch the warning signs	Preoccupation with rules, secrecy around eating, bingeing in the eating window, low energy or mood, menstrual changes, hair loss, dizziness. Stop if any of these appear and review.

A few practical anchors:

• The CSIRO Total Wellbeing Diet / Flexi Diet is an Australian-developed structured programme using 5:2 and modified protocols, with evidence in AU adults.
• Diabetes Australia and the Royal Australian and New Zealand College of Physicians have AU-tailored resources on diet and metabolic disease.
• Dietitians Australia maintains a public directory of accredited practising dietitians.

When to stop or seek review

Stop intermittent fasting and seek review with a GP if:

• Hypoglycaemia symptoms (sweating, shaking, confusion) develop, especially on insulin or sulfonylureas
• Persistent dizziness, headache, or new palpitations
• Menstrual cycle changes or fertility concerns
• Significant low mood, irritability, or anxiety triggered by the eating pattern
• Disordered eating behaviour or thoughts emerge or recur
• Weight loss is faster than is sustainable (>1 kg/week sustained) or BMI drops below 18.5
• Hair loss, easy bruising, fatigue out of keeping with energy intake
• New medication is started where timing conflicts with the eating window

What this article is and is not

This is general health information drawn from current Australian general practice guidelines, major randomised trials of intermittent fasting, and umbrella reviews of the trial evidence. It is not personal medical advice and does not create a doctor–patient relationship. Decisions about whether intermittent fasting is suitable, which pattern, and how to integrate it with medication and other care are made with your own GP and treating clinicians, who know your history.

For Australian consumer-friendly summaries: HealthDirect — Intermittent fasting, Better Health Channel — Weight loss, and Diabetes Australia where relevant to existing diabetes.

---

Sources cited

1. RACGP — Obesity and weight management resources
2. Therapeutic Guidelines (eTG)
3. Australian Medicines Handbook
4. Diabetes Australia
5. NHMRC — Australian Dietary Guidelines
6. Dietitians Australia
7. CSIRO — Health and Biosecurity research
8. HealthDirect — Intermittent fasting
9. Better Health Channel — Weight loss
10. Liu et al. — Time-restricted eating + calorie restriction RCT (NEJM 2022)
11. Trepanowski et al. — Alternate-day fasting RCT (JAMA Intern Med 2017)
12. Sutton et al. — Early time-restricted feeding (Cell Metab 2018)
13. Carter et al. — 5:2 vs daily energy restriction in type 2 diabetes (JAMA Netw Open 2018)
14. Patikorn et al. — umbrella review intermittent fasting (JAMA Netw Open 2021)
15. Beyond Blue, Butterfly Foundation, InsideOut Institute